Skip to content
DataLookout
Menu

GRAVITINCT05197049

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

StatusActive, Not Recruiting
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 54 versions: 39 with changes below, 11 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Study completion moved earlier from Oct 30, 2028 to Mar 27, 2028
    • Site details revised at 7 of 345 sites
  2. Notable Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 6 of 6 entries
    • Study sites revised (345)
    • Publications: details revised at 1 of 1 entry
  3. Minor Study sites revised (345)v52
  4. Minor Study sites revised (345)v51
  5. Minor Site details revised at 1 of 345 sitesv49
Show 34 earlier versionsHide 34 earlier versions
  1. Minor Study sites: 344 to 345v47
  2. Minor Study sites: 343 to 344v46
  3. Minor Study sites: 344 to 343v45
  4. Minor Site details revised at 1 of 344 sitesv44
  5. Minor Study completion date: Mar 27, 2028 to Oct 30, 2028v41
  6. Minor Study sites revised (344)v40
  7. Minor Study sites: 341 to 344v38
  8. Notable Results first posted: Feb 21, 2025v32 Show 4 more changesShow less
    • Primary endpoints revised (2)
    • Study sites: 342 to 341
    • Study completion date: Mar 31, 2025 to Mar 27, 2028
    • Secondary endpoints: 4 to 6
  9. Minor Secondary endpoints: details revised at 1 of 4 entries
    • Study description shortened, about 95 words
    • Study sites revised (342)
    v31
  10. Minor Study sites revised (342)v30
  11. Minor Site details revised at 2 of 342 sitesv29
  12. Minor Study sites revised (342)v28
  13. Minor Study sites revised (342)v27
  14. Minor Study sites revised (342)v26
  15. Minor Study sites revised (342)v25
  16. Minor Study completion date: Jun 30, 2025 to Mar 31, 2025
    • Study sites revised (342)
    v24
  17. Minor Study sites revised (342)v23
  18. Minor Study sites revised (342)v22
  19. Minor Study sites revised (342)v21
  20. Minor Study sites: 341 to 342v20
  21. Minor Study sites revised (341)v19
  22. Minor Study sites: 342 to 341
    • Study completion date: Aug 13, 2025 to Jun 30, 2025
    v18
  23. Minor Study sites: 341 to 342
    • Study completion date: Sep 9, 2025 to Aug 13, 2025
    v17
  24. Minor Study sites revised (341)v16
  25. Minor Primary completion date: Feb 27, 2023 to Jul 4, 2023
    • Study completion date: Aug 14, 2025 to Sep 9, 2025
    v14
  26. Minor Study sites revised (341)v13
  27. Minor Study sites revised (341)v12
  28. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 318 to confirmed 350
    • Study sites revised (341)
    v11
  29. Minor Study sites: 530 to 341
    • Study completion date: Aug 13, 2025 to Aug 14, 2025
    v10
  30. Minor Study sites: 537 to 530
    • Primary completion date changed from estimate of Jul 6, 2023 to Feb 27, 2023
    v9
  31. Minor Study sites: 532 to 537
    • Study completion date: Feb 10, 2025 to Aug 13, 2025
    v8
  32. Minor Study sites: 500 to 532v7
  33. Minor Study sites: 384 to 500v6
  34. Minor Study sites: 327 to 384v5
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of Participants Who Achieved Clinical Remission at Week 12
Timeframe: At Week 12
Percentage of Participants Who Achieved Endoscopic Response at Week 12
Timeframe: At Week 12

Secondary (6)

Percentage of Participants Who Achieved Clinical Remission at Week 24
Percentage of Participants Who Achieved Patient-reported Outcome (PRO)-2 Remission at Week 12
Percentage of Participants Who Achieved Clinical Response at Week 12
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 48
Percentage of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through Week 48
Show 1 moreShow less
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation of Study Drug Through Week 48

Arms and interventions

Group 1: GuselkumabExperimental

Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 2) injection subcutaneously.

Group 2: GuselkumabExperimental

Participants will receive guselkumab (Dose 1) injection subcutaneously followed by guselkumab (Dose 3) injection subcutaneously.

Group 3: PlaceboPlacebo comparator

Participants will receive placebo injection subcutaneously.

Drugs: Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo

Sites

345 sites in 27 countries

United States 77, Poland 44, Japan 42, Brazil 28, China 26, South Korea 18, Germany 13, France 11, Hungary 10, Turkey (Türkiye) 8, Spain 7, Bosnia and Herzegovina 6, Jordan 6, Belgium 5, Czechia 5, Israel 5, Malaysia 5, Taiwan 5, Croatia 4, Italy 4, Netherlands 3, Slovakia 3, Australia 2, Canada 2, Denmark 2, Lithuania 2, New Zealand 2